What’s Happening With Amgen Stock? - Forbes

4 days ago · Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...

CouponFollow Extension

7%
OFF

What’s Happening With Amgen Stock? - Forbes

1 week from now

forbes.com

7%
OFF

What’s Driving Growth For Amgen Stock? - Forbes

1 week from now

Dec 14, 2022 · Amgen stock (NASDAQ NDAQ +0.7%: AMGN) has seen a substantial 23% rise this year, far better than the broader S&P500 index, which is down 16%. However, in the …

forbes.com

$349
OFF

What Analysts Are Saying About Amgen Stock - Nasdaq

1 week from now

3 days ago · Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a low estimate of $215.00.

nasdaq.com

2%
OFF

Amgen (NASDAQ:AMGN) Stock Rises Again On Bone Density Data …

1 week from now

4 days ago · What’s Happening with AMGN Stock After falling yesterday on these bone density concerns, AMGN stock is trending upward again. As of this writing, it is up 2% for the day , …

nasdaq.com

17%
OFF

Is Amgen Stock Fully Valued After A 17% Rise In A Month? - Forbes

1 week from now

Aug 14, 2023 · If we look at the longer term, AMGN stock is up 16% from levels seen in late 2021, faring better than the S&P 500 index, down around 6%. This 16% rise for Amgen AMGN stock …

forbes.com

3%
OFF

AMGN News Today | Why Did Amgen Stock Go Down Today?

1 week from now

6 days ago · Biechele Royce Advisors decreased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.3% during the 3rd quarter, according to the company in its most recent …

marketbeat.com

$2.25
OFF

Amgen Inc. (AMGN) Latest Stock News & Headlines - Yahoo Finance

1 week from now

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024, to all ...

yahoo.com

30%
OFF

Will Amgen Stock Continue To See Higher Levels Driven By Its

1 week from now

May 8, 2024 · Firstly, let us look at Amgen’s stock performance. AMGN stock has shown gains of 30% from levels of $230 in early January 2021 to around $300 now, vs. an increase of about …

forbes.com

39%
OFF

What’s Driving Amgen Stock Higher? - Forbes

1 week from now

Sep 7, 2022 · This 39% growth for AMGN stock since late 2017 can primarily be attributed to 1. the company’s P/S ratio rising 21% to 4.9x trailing revenues, from 4.1x in 2017, 2. Amgen’s …

forbes.com

16%
OFF

2 Reasons To Buy Amgen Stock, And 1 Reason To Be Cautious

1 week from now

2 days ago · While Amgen's (AMGN-4.16%) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, …

fool.com

6%
OFF

Up 970-Fold Since Its IPO, Amgen Stock Could Be Overvalued

1 week from now

Aug 14, 2023 · Amgen is overvalued according to 13 Wall Street analysts. As TipRanks noted, their average 12-month price target is $247.67 — about 6% below its August 14 price. …

forbes.com

18%
OFF

Amgen Revenue 2014-2024 - Stock Analysis

1 week from now

Amgen Revenue. Amgen had revenue of $8.50B in the quarter ending September 30, 2024, with 23.18% growth. This brings the company's revenue in the last twelve months to $32.53B, up …

stockanalysis.com

48%
OFF

What's Happening With Goldman Stock? - Forbes

1 week from now

2 days ago · The increase in GS stock over the last 4-year period has been far from consistent and has largely been as volatile as the S&P 500. Returns for the stock were 48% in 2021, -8% …

forbes.com

12%
OFF

What's Happening With SNAP Stock? - Forbes

1 week from now

4 days ago · a 12% rise in the company’s P/S ratio to 3.4x now, versus 3.1x in 2022;; a 12% rise in the company’s revenue from $4.6 billion to $5.2 billion over the same period; and; a 0.1% …

forbes.com

$300
OFF

Trump’s ‘A Star Is Born’ Comment Adds $300 Billion To ... - Forbes

1 week from now

4 days ago · Tesla stock now trades at levels last seen around early 2022 and its market cap now stands at over $1.1 trillion, up more than $300 billion in less than a week. Investors are …

forbes.com

FAQs about What’s Happening With Amgen Stock? - Forbes Coupon?

Why did Amgen stock fall 7%?

CHINA - 2024/09/17: In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images) Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. ...

Is Amgen stock a good stock to buy?

Amgen stock (NASDAQ NDAQ 0.0%: AMGN) has seen a substantial 23% rise this year, far better than the broader S&P500 index, which is down 16%. However, in the longer term, AMGN stock is up 42% from levels seen in late 2018, slightly underperforming the S&P 500 index, up about 65%. ...

Will Amgen stock disappoint without faster growth?

Without faster growth, the stock could disappoint. While Amgen reported modest growth in the second quarter, the biopharma giant exceeded revenue and profit expectations and lifted its full-year guidance. Q2 Revenue: $6.99 billion — up 6.9% and $30 million ahead of analysts’ forecast. ...

Are Amgen insiders buying or selling stock?

In the past three months, Amgen insiders have not sold or bought any company stock. Only 0.69% of the stock of Amgen is held by insiders. 76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Receive AMGN Stock News and Ratings via Email ...

What was Amgen's stock price on January 1st 2024?

Amgen's stock was trading at $288.02 on January 1st, 2024. Since then, AMGN shares have increased by 10.0% and is now trading at $316.74. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Tuesday, August, 6th. ...

Will Amgen (AMGN) beat its earnings forecast?

Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs. Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. ...